OPK

Opko Health Inc

OPK, USA

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

https://www.opko.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OPK
stock
OPK

Does OPKO Health’s Recent Rebound Signal a Mispriced Opportunity in 2025? simplywall.st

Read more →
OPK
stock
OPK

OPKO Health (NASDAQ:OPK) Stock Rating Lowered by Wall Street Zen MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3.5583

Analyst Picks

Strong Buy

2

Buy

4

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.79

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.69 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

3.07 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-24.91 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.53

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 30.13% of the total shares of Opko Health Inc

1.

Rubric Capital Management LP

(6.0207%)

since

2025/06/30

2.

Vanguard Group Inc

(4.8173%)

since

2025/06/30

3.

BlackRock Inc

(3.962%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(1.5249%)

since

2025/07/31

5.

Geode Capital Management, LLC

(1.3133%)

since

2025/06/30

6.

iShares Russell 2000 ETF

(1.0941%)

since

2025/08/31

7.

Vanguard Small Cap Index

(1.0908%)

since

2025/07/31

8.

State Street Corp

(1.0811%)

since

2025/06/30

9.

UBS Group AG

(0.7206%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6232%)

since

2025/07/31

11.

Weiss Asset Management LP

(0.5993%)

since

2025/06/30

12.

Fidelity Small Cap Index

(0.4542%)

since

2025/06/30

13.

Northern Trust Corp

(0.4387%)

since

2025/06/30

14.

Charles Schwab Investment Management Inc

(0.4221%)

since

2025/06/30

15.

Marshall Wace Asset Management Ltd

(0.4218%)

since

2025/06/30

16.

iShares Russell 2000 Value ETF

(0.4057%)

since

2025/08/31

17.

Goldman Sachs Group Inc

(0.3553%)

since

2025/06/30

18.

Vanguard Small Cap Value Index Inv

(0.352%)

since

2025/07/31

19.

Fidelity Extended Market Index

(0.3098%)

since

2025/07/31

20.

Vanguard Small Cap Growth Index Inv

(0.3056%)

since

2025/07/31

21.

Schwab US Small-Cap ETF™

(0.2669%)

since

2025/08/30

22.

iShares Biotechnology ETF

(0.2655%)

since

2025/08/31

23.

Morgan Stanley - Brokerage Accounts

(0.2594%)

since

2025/06/30

24.

Awm Investment Company Inc

(0.252%)

since

2025/06/30

25.

Dimensional Fund Advisors, Inc.

(0.2431%)

since

2025/06/30

26.

Graham Capital Management

(0.2408%)

since

2025/06/30

27.

Bank of America Corp

(0.2402%)

since

2025/06/30

28.

Two Sigma Investments LLC

(0.2314%)

since

2025/06/30

29.

Whitefort Capital Management, LP.

(0.2235%)

since

2025/06/30

30.

Vanguard Russell 2000 ETF

(0.2169%)

since

2025/07/31

31.

Y.D. More Investments Ltd

(0.1926%)

since

2025/06/30

32.

Jane Street Group LLC

(0.1744%)

since

2025/06/30

33.

Invesco S&P 500 ETF

(0.1602%)

since

2025/07/31

34.

State St Russell Sm Cap® Indx SL Cl I

(0.1502%)

since

2025/08/31

35.

Invesco RAFI US 1500 Small-Mid ETF

(0.1195%)

since

2025/08/29

36.

Fidelity Total Market Index

(0.1177%)

since

2025/07/31

37.

Vanguard Health Care ETF

(0.1175%)

since

2025/07/31

38.

Extended Equity Market Fund K

(0.1169%)

since

2025/06/30

39.

Schwab Small Cap Index

(0.1146%)

since

2025/07/31

40.

NT R2000 Index Fund - NL

(0.1103%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.065

Latest Release

Date

2025-09-30

EPS Actual

0.03

EPS Estimate

-0.06

EPS Difference

0.09

Surprise Percent

150%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Moderate Quality(5.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.